Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

159 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The role of Aurora-A inhibitors in cancer therapy.
Agnese V, Bazan V, Fiorentino FP, Fanale D, Badalamenti G, Colucci G, Adamo V, Santini D, Russo A. Agnese V, et al. Among authors: badalamenti g. Ann Oncol. 2007 Jun;18 Suppl 6:vi47-52. doi: 10.1093/annonc/mdm224. Ann Oncol. 2007. PMID: 17591831 Free article. Review.
Antiblastic drug combinations with ifosfamide: an update.
Fulfaro F, Valerio MR, Badalamenti G, Gebbia N, Russo A. Fulfaro F, et al. Among authors: badalamenti g. Oncology. 2003;65 Suppl 2:21-30. doi: 10.1159/000073354. Oncology. 2003. PMID: 14586143 Review.
A new germline mutation in BRCA1 gene in a sicilian family with ovarian cancer.
Calò V, Agnese V, Gargano G, Corsale S, Gregorio V, Cascio S, Cammareri P, Bruno L, Augello C, Gullo A, Sisto PS, Badalamenti G, Valerio MR, Napoli L, Gebbia N, Bazan V, Russo A. Calò V, et al. Among authors: badalamenti g. Breast Cancer Res Treat. 2006 Mar;96(1):97-100. doi: 10.1007/s10549-005-9049-z. Epub 2005 Oct 22. Breast Cancer Res Treat. 2006. PMID: 16244786
A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma.
Valerio MR, Tagliaferri P, Raspagliesi F, Fulfaro F, Badalamenti G, Arcara C, Cicero G, Russo A, Venuta S, Guarneri G, Gebbia N. Valerio MR, et al. Among authors: badalamenti g. Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:79-85. doi: 10.1111/j.1525-1438.2006.00324.x. Int J Gynecol Cancer. 2006. PMID: 16515572 Clinical Trial.
Founder mutations in BRCA1 and BRCA2 genes.
Ferla R, Calò V, Cascio S, Rinaldi G, Badalamenti G, Carreca I, Surmacz E, Colucci G, Bazan V, Russo A. Ferla R, et al. Among authors: badalamenti g. Ann Oncol. 2007 Jun;18 Suppl 6:vi93-8. doi: 10.1093/annonc/mdm234. Ann Oncol. 2007. PMID: 17591843 Free article. Review.
4843delC of the BRCA1 gene is a possible founder mutation in Southern Italy (Sicily).
Russo A, Calò V, Augello C, Bruno L, Agnese V, Schirò V, Barbera F, Cascio S, Foddai E, Badalamenti G, Intrivici C, Cajozzo M, Gulotta G, Surmacz E, Colucci G, Gebbia N, Bazan V. Russo A, et al. Among authors: badalamenti g. Ann Oncol. 2007 Jun;18 Suppl 6:vi99-102. doi: 10.1093/annonc/mdm235. Ann Oncol. 2007. PMID: 17591844 Free article.
159 results